Articles related to CARDIOVASCULAR EVENTS

To assess short-term risk for severe cardiovascular events (excluding myocarditis and pericarditis) after COVID-19 vaccination, adults younger than 75 years hospitalized for PE, acute MI, hemorrhagic stroke, or ischemic stroke (73,325 events) were reviewed in relation to a 1st or 2nd COVID vaccine dose. No association was found between the Pfizer–BioNTech or Moderna vaccine and severe cardiovascular events. The first dose of the Oxford–AstraZeneca vaccine was associated with acute MI and PE in the second week after vaccination. An association with MI in the second week after a single dose of the Janssen vaccine could not be ruled out.

The USPSTF comes to the conclusion that statin use has at least a moderate net benefit for adults aged 40 to 75 who have no prior history of CVD, at least one CVD risk factor, and an estimated 10-year CVD event risk of 10% or greater. There is at least a marginal net benefit from using statins to prevent CVD events and all-cause mortality in adults aged 40 to 75 who have no prior history of CVD, at least one of these risk factors, and an estimated 10-year CVD event risk of 7.5% to less than 10%. Still, is the evidence enough?

This review with case example explores pericarditis and myocarditis and implications on limiting exercise. The authors summarize relevant guidelines and provide their own conclusion and guidance. They offer a helpful algorithm combining the ESC, ACC, and AHA guidelines and suggest an additional element around limiting heart rate during an acute inflammatory episode.

What is the best strategy for preventing stroke in patients with non-valvular AF: anticoagulants or left atrial appendage occlusion (LAAO)? The answer depends on the individual patient’s combination of stroke and bleeding risks. In this study, combined risks favored LAAO for higher bleeding risk, but that benefit became less certain at higher stroke risks.

A conversation with Ann Marie Navar, MD, PhD, associate professor of cardiology at UT Southwestern in Dallas, Texas and associate editor of JAMA Cardiology, who discusses common statin-related myths, the safety of statin therapy, and reliable sources of information for patients.

The story of David Bennett, age 57, who had severe cardiac failure and was denied a traditional human heart transplant from several programs when he ultimately agreed to the experimental xenotransplant. On day 34, the patient showed no signs of rejection of the porcine heart, but by day 49, sudden diastolic thickening and antibody-mediated failure of the xenograft prevented any lifesaving measures, and he died on day 60.